Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
99 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Opium (Opioid) Addiction - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Opium (Opioid) Addiction - Pipeline Review, H2 2016', provides an overview of the Opium (Opioid) Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction - The report reviews pipeline therapeutics for Opium (Opioid) Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Opium (Opioid) Addiction therapeutics and enlists all their major and minor projects - The report assesses Opium (Opioid) Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Opium (Opioid) Addiction - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Opium (Opioid) Addiction pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Opium (Opioid) Addiction Overview 9 Therapeutics Development 10 Pipeline Products for Opium (Opioid) Addiction - Overview 10 Pipeline Products for Opium (Opioid) Addiction - Comparative Analysis 11 Opium (Opioid) Addiction - Therapeutics under Development by Companies 12 Opium (Opioid) Addiction - Therapeutics under Investigation by Universities/Institutes 14 Opium (Opioid) Addiction - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Unknown Stage Products 18 Opium (Opioid) Addiction - Products under Development by Companies 19 Opium (Opioid) Addiction - Products under Investigation by Universities/Institutes 20 Opium (Opioid) Addiction - Companies Involved in Therapeutics Development 21 Alkermes Plc 21 Aoxing Pharmaceutical Company, Inc 22 BioDelivery Sciences International, Inc. 23 Camurus AB 24 Foresee Pharmaceuticals, LLC 25 Heron Therapeutics, Inc. 26 Indivior Plc 27 INSYS Therapeutics, Inc. 28 Omeros Corporation 29 Pfizer Inc. 30 Relmada Therapeutics, Inc. 31 Teva Pharmaceutical Industries Ltd. 32 Titan Pharmaceuticals, Inc. 33 Zynerba Pharmaceuticals, Inc. 34 Opium (Opioid) Addiction - Therapeutics Assessment 35 Assessment by Monotherapy Products 35 Assessment by Combination Products 36 Assessment by Target 37 Assessment by Mechanism of Action 39 Assessment by Route of Administration 41 Assessment by Molecule Type 43 Drug Profiles 45 (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 (buprenorphine hydrochloride + samidorphan l-malate) - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 buprenorphine hydrochloride - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 buprenorphine hydrochloride - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 buprenorphine hydrochloride - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 buprenorphine hydrochloride depot - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 buprenorphine hydrochloride ER - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 buprenorphine hydrochloride long acting - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 buprenorphine hydrochloride SR - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 cannabidiol - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 cannabidiol - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 FP-004 - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 naltrexone hydrochloride - Drug Profile 71 Product Description 71 Mechanism Of Action 71 R&D Progress 71 naltrexone hydrochloride - Drug Profile 72 Product Description 72 Mechanism Of Action 72 R&D Progress 72 OMS-405 - Drug Profile 73 Product Description 73 Mechanism Of Action 73 R&D Progress 73 OMS-527 - Drug Profile 74 Product Description 74 Mechanism Of Action 74 R&D Progress 74 ORP-107 - Drug Profile 76 Product Description 76 Mechanism Of Action 76 R&D Progress 76 PF-5006739 - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 samidorphan l-malate - Drug Profile 78 Product Description 78 Mechanism Of Action 78 R&D Progress 78 TA-CD - Drug Profile 80 Product Description 80 Mechanism Of Action 80 R&D Progress 80 TEV-90109 - Drug Profile 81 Product Description 81 Mechanism Of Action 81 R&D Progress 81 Vaccine for Opium Addiction - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 Opium (Opioid) Addiction - Dormant Projects 83 Opium (Opioid) Addiction - Discontinued Products 84 Opium (Opioid) Addiction - Product Development Milestones 85 Featured News & Press Releases 85 Aug 16, 2016: Indivior Announces Positive Top-line Phase 3 Pivotal Study Results for RBP-6000 Buprenorphine Monthly Depot for the Treatment of Opioid Use Disorder 85 Aug 02, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Juan on August 5, 6 and 7 for Qualified Healthcare Providers 86 Jul 26, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Burlington on July 29 and 30 for Qualified Healthcare Providers 87 Jul 19, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings on July 22, 23 and 24 for Qualified Healthcare Providers in US 88 Jul 19, 2016: Buprenorphine implants may be effective relapse prevention tool for adults with opioid dependence 88 Jul 12, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Tampa on July 15, 16 and 17 for Qualified Healthcare Providers 89 Jun 29, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Antonio on July 8 and 9 for Qualified Healthcare Providers 90 Jun 21, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in St. Louis on June 24 and 25 for Qualified Healthcare Providers 90 Jun 20, 2016: Titan Pharmaceuticals Announces First Patients Treated With Probuphine For Opioid Dependence 91 Jun 16, 2016: Probuphine (buprenorphine) Implant Phase 3 Data Presented at CPDD Annual Scientific Meeting 92 Jun 15, 2016: Titan Pharmaceuticals Announces Rigorous Sensitivity Analyses Confirm Effectiveness of Probuphine for Opioid Dependence 92 Jun 14, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in San Francisco on June 17, 18 and 19 for Qualified Healthcare Providers 93 Jun 13, 2016: Titan Pharmaceuticals Receives $15 Million Milestone Payment Following FDA Approval of Probuphine 94 Jun 09, 2016: Braeburn Pharmaceuticals to Conduct First Series of Probuphine (buprenorphine) Implant Trainings in Louisville on June 10, 11 and 12 for Qualified Healthcare Providers 95 Jun 07, 2016: MonoSol Rx Wins Patent Infringement Suit Against Par Pharmaceutical and Watson Pharmaceuticals Related to Suboxone Sublingual Film 96 Appendix 97 Methodology 97 Coverage 97 Secondary Research 97 Primary Research 97 Expert Panel Validation 97 Contact Us 97 Disclaimer 98
List of Tables
Number of Products under Development for Opium (Opioid) Addiction, H2 2016 10 Number of Products under Development for Opium (Opioid) Addiction - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Comparative Analysis by Late Stage Development, H2 2016 15 Comparative Analysis by Clinical Stage Development, H2 2016 16 Comparative Analysis by Early Stage Development, H2 2016 17 Comparative Analysis by Unknown Stage Development, H2 2016 18 Products under Development by Companies, H2 2016 19 Products under Investigation by Universities/Institutes, H2 2016 20 Opium (Opioid) Addiction - Pipeline by Alkermes Plc, H2 2016 21 Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company, Inc, H2 2016 22 Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International, Inc., H2 2016 23 Opium (Opioid) Addiction - Pipeline by Camurus AB, H2 2016 24 Opium (Opioid) Addiction - Pipeline by Foresee Pharmaceuticals, LLC, H2 2016 25 Opium (Opioid) Addiction - Pipeline by Heron Therapeutics, Inc., H2 2016 26 Opium (Opioid) Addiction - Pipeline by Indivior Plc, H2 2016 27 Opium (Opioid) Addiction - Pipeline by INSYS Therapeutics, Inc., H2 2016 28 Opium (Opioid) Addiction - Pipeline by Omeros Corporation, H2 2016 29 Opium (Opioid) Addiction - Pipeline by Pfizer Inc., H2 2016 30 Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics, Inc., H2 2016 31 Opium (Opioid) Addiction - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 32 Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals, Inc., H2 2016 33 Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016 34 Assessment by Monotherapy Products, H2 2016 35 Assessment by Combination Products, H2 2016 36 Number of Products by Stage and Target, H2 2016 38 Number of Products by Stage and Mechanism of Action, H2 2016 40 Number of Products by Stage and Route of Administration, H2 2016 42 Number of Products by Stage and Molecule Type, H2 2016 44 Opium (Opioid) Addiction - Dormant Projects, H2 2016 83 Opium (Opioid) Addiction - Discontinued Products, H2 2016 84
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.